Menlo Therapeutics ’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis

REDWOOD CITY, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced positive top-line...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials